Transplantacja mikroflory jelitowej – perspektywy i bezpieczeństwo
DOI:
https://doi.org/10.21164/pomjlifesci.98Słowa kluczowe:
transplantacja mikroflory jelitowej, mikrobiota jelitowa, zakażenia Clostridium difficileAbstrakt
Mikrobiota przewodu pokarmowego, zarówno bezpośrednio, jak i pośrednio, wpływa na zachowanie homeostazy w organizmie człowieka. Mikroorganizmy jelitowe są szczególnie istotne ze względu na ich udział w rozwoju układu immunologicznego, ochronę przed patogenami, jak również funkcje metaboliczne i troficzne. Pomimo że skuteczność probiotyków oraz prebiotyków w łagodzeniu objawów szeregu chorób gastroenterologicznych została wielokrotnie potwierdzona, to w dalszym ciągu rośnie zainteresowanie metodą transplantacji kału. Skuteczność tej terapii potwierdzono przede wszystkim w leczeniu rzekomobłoniastego zapalenia jelita grubego. Coraz częściej dyskutuje się o możliwości zastosowania tej metody w leczeniu innych chorób przebiegających z dysbiozą jelitową. Transplantacja mikroflory kałowej, z uwagi na szybki efekt terapeutyczny, minimalne ryzyko działań niepożądanych, stosunkowo niski koszt i zdolność do modulowania składu mikroflory jelitowej wydaje się wartościową, alternatywną metodę leczenia w przypadku wybranych chorób przewodu pokarmowego. Celem pracy było przedstawienie tematu transplantacji kału, w tym jego zastosowanie w leczeniu innych chorób gastroenterologicznych.
Bibliografia
Candela M., Rampelli S., Turroni S., Severgnini M., Consolandi C., De Bellis G. et al.: Unbalance of intestinal microbiota in atopic children. BMC Microbiol. 2012, 12, 95–103.
Mai V., Young C.M., Ukhanova M., Wang X., Sun Y., Casella G. et al.: Fecal microbiota in premature infants prior to necrotizing enterocolitis. PLoS ONE. 2011, 6 (6), e20647.
Cani P.D.: Gut microbiota and obesity: lessons from the microbiome. Brief Funct Genomics. 2013, 12 (4), 381–387.
Arthur J.C., Jobin C.: The complex interplay between inflammation, the microbiota and colorectal cancer. Gut Microbes. 2013, 4 (3), 253–258.
Manichanh C., Borruel N., Casellas F., Guarner F.: The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012, 9 (10), 599–608.
Turnbaugh P.J., Ley R.E., Hamady M., Fraser‑Liggett
C.M., Knight R., Gordon J.I.: The human microbiome project. Nature. 2007, 449, 804–810.
Lund‑Tønnesen S., Berstad A., Schreiner A., Midtvedt T.: Clostridium difficile‑associated diarrhea treated with homologous feces. Tidsskr Nor Laegeforen. 1998, 118 (7), 1027–1030.
Persky S., Brandt L.J.: Treatment of recurrent Clostridium difficile‑associated diarrhea by administration of donated stool directly though a colonoscope. Am J Gastroenterol. 2000, 95 (11), 3283–3285.
Silverman M.S., Davis I., Pillai D.R.: Success of self‑administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol. 2010, 8 (5), 471–473.
Aas J., Gessert C.E., Bakken J.S.: Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003, 36 (5), 580–585.
Brandt L.J., Aroniadis O.C.: An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013, 78 (2), 240–249.
Louie T., Cannon K., O’grady H., Wu K., Ward L.: Fecal microbiome transplantation (FMT) via oral fecal microbial capsules for recurrent Clostridium difficile infection (rCDI). IDWeek 2013, Abstract 89.
Zhang F., Luo W., Shi Y., Fan Z., Ji G.: Should we standardize the 1700‑year‑ old fecal microbiota transplantation? Am J Gastroenterol. 2012, 107 (11), 1755–1756.
Eiseman B., Silen W., Bascom G.S., Kauvar A.J.: Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958, 44 (5), 854–859.
Pathak R., Enuh H.A., Patel A., Wickremesinghe P.: Treatment of relapsing Clostridium difficile infection using fecal microbiota transplantation. Clin Exp Gastroenterol. 2013, 7, 1–6.
Bakken J.S., Polgreen P.M., Beekmann S.E., Riedo F.X., Streit J.A.: Treatment approaches including fecal microbiota transplantation for recurrentClostridium difficile infection (RCDI) among infectious disease physicians. Anaerobe. 2013, 24, 20–24.
Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C. et al.: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010, 31 (5), 431–455.
Surawicz C.M., Brandt L.J., Binion D.G.,Ananthakrishnan A.N., Curry S.R., Gilligan P.H. et al.: Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013, 108 (4), 478–498.
Bakken J.S.: Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe. 2009, 15 (6), 285–289.
Huebner E.S., Surawicz C.M.: Treatment of recurrent Clostridium difficile diarrhea. Gastroenterol Hepatol 2006, 2 (3), 203–208.
Schwan A., Sjölin S., Trottestam U., Aronsson B.: Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet. 1983, 2, 845.
Chang J.Y., Antonopoulos D.A., Kalra A., Tonelli A., Khalife W.T., Schmidt T.M. et al.: Decreased diversity of the fecal microbiome in recurrent Clostridium difficile‑associated diarrhea. J Infect Dis. 2008, 197 (3), 435–438.
Goldin B.R., Gorbach S.L., Saxelin M., Barakat S., Gualtieri L., Salminen S.: Survival of Lactobacillus species (strain GG) in human gastrointestinal tract. Dig Dis Sci. 1992, 37 (1), 121–128.
Grehan M.J., Borody T.J., Leis S.M., Campbell J., Mitchell H., Wettstein A.: Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010, 44 (8), 551–561.
Khoruts A., Dicksved J., Jansson J.K., Sadowsky M.J.: Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile‑associated diarrhea. J Clin Gastroenterol. 2010, 44 (5), 354–360.
Hamilton M.J., Weingarden A.R., Unno T., Khoruts A., Sadowsky M.J.: High‑throughput DNA sequence analysis reveals stable engraftment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes. 2013, 4 (2), 125–135.
Brandt L.J., Aroniadis O.C., Mellow M., Kanatzar A., Kelly C., Park T. et al.: Long‑term follow‑up of colonoscopic fecal microbiota transplantation for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012, 107 (7), 1079–1087.
van Nood E., Vrieze A., Nieuwdorp M., Fuentes S., Zoetendal E.G., de Vos W.M. et al.: Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013, 368 (5), 407–415.
Yoon S.S., Brandt L.J.: Treatment of refractory/recurrent C. difficile‑associated disease by donated stool transplanted via colonoscopy. A case series of 12 patients. J Clin Gastroenterol. 2010, 44 (8), 562–566.
Rohlke F., Surawicz C.M., Stollman N.: Fecal flora reconstitution for recurrent Clostridium difficile infection: results and methodology. J Clin
Gastroenterol. 2010, 44 (8), 567–570.
Borody T.J., Warren E.F., Leis S.M., Surace R., Ashman O., Siarakas S.: Bacteriotherapy using fecal flora: toying with human motions. J Clin Gastroenterol.
, 38 (6), 475–483.
Borody T.J., Khoruts A.: Fecal microbiota transplantation and emerging applications. Nat Rev Gastroenterol Hepatol. 2011, 9 (2), 88–96.
Anderson J.L., Edney R.J., Whelan K.: Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. Aliment Pharmacol Ther. 2012, 36 (6), 503–516.
Damman C.J., Miller S.I., Surawicz C.M., Zisman T.L.: The microbiome and inflammatory bowel disease: is there a role for fecal microbiota transplantation? Am J Gastroenterol. 2012, 107 (10), 1452–1459.
Turnbaugh P.J., Ley R.E., Mahowald M.A., Magrini V., Mardis E.R., Gordon J.I.: An obesity‑associated gut microbiome with increased capacity for energy harvest. Nature. 2006, 444, 1027–1031.
Vrieze A., Van Nood E., Holleman F., Salojärvi J., Kootte R.S., Bartelsman J.F. et al.: Transfer of intestinal microbiota from lean donors increases insulin sensitivity in subjects with metabolic syndrome. Gastroenterology. 2012, 143 (4), 913–916.e7.
Anathaswamy A.: Faecal transplant eases symptoms of Parkinson’s. New Scientist. 2011, 209, 8–9.
Rajilić‑Stojanović M., Biagi E., Heilig H.G., Kajander K., Kekkonen R.A., Tims S. et al.: Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011, 141 (5), 1792–1801.
Borody T.J., Leis S., Campbell J., Torres M., Nowak A.: Fecal microbiota transplantation (FMT) in multiple sclerosis (MS). Am J Gastroenterol. 2011, 106, S352.
Borody T.J., Rosen D.M., Torres M.: Myoclonus‑dystonia
(M‑D) mediated by GI microbiota diarrhoea treatment improves M‑D sympoms. Am J Gastroenterol. 2011, 106, S352.
Finegold S.M., Molitors D., Song Y., Liu C., Vaisanen M.L., Bolte E. et al.: Gastrointestinalmicro flora studies in late‑onset autism. Clin Infect Dis. 2002, 35 (Suppl. 1), S6–S16.
Bakken J.S., Borody T., Brandt L.J., Brill J.V., Demarco D.C., Franzos M.A. et al.: Treating Clostridium difficile infection with fecal microbiota transplantation.Clin Gastroenterol Hepatol. 2011, 9 (12), 1044–1049.
Hamilton M.J., Weingarden A.R., Sadowsky M.J., Khoruts A.: Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012, 107 (5), 761–767.
Gough E., Shaikh H., Manges A.R.: Systematic review of intestinal microbiotatransplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011, 53 (10), 994–1002.
